AstraZeneca ($AZN) generated 120 mentions from six distinct FinTwit voices over a 12-month period from July 2025 to June 2026, with @jacobplieth accounting for 117 of those mentions. The biotech category dominated discussion of the stock. @adamfeuerstein and @investmentguru_ were the next most active voices, with 6 and 1 mentions respectively. The most recent mentions centered on a Phase 3 trial failure for Wainua in transthyretin cardiomyopathy (ATTR-CM), which triggered a significant stock decline on July 9, 2026.